A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled XQ-001 in Healthy Subjects

Phase 1 Active not recruiting 58 enrolled Brilliant Inspiration Biotherapeutics

RandomizedSequentialQuadruple-blindOther

Summary

The primary study objective is to evaluate the safety and tolerability of XQ-001 for inhalation after single and multiple nebulized inhalation administration in healthy Chinese adult subjects.

Timeline

Start: 2024-08-01
Primary completion: 2025-03-31
Completion: 2025-05-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XQ-001	Unknown	—	Inhaled

Indications

No indication recorded.